Top

Current Dermatology Reports

Published in:

01-06-2018 | Skin Cancer (A Marghoob and M Marchetti, Section Editors)

What Is New in CTCL—Pathogenesis, Diagnosis, and Treatments

Authors: Brittany O. Dulmage, Betty Y. Kong, Kassandra Holzem, Joan Guitart

Published in: Current Dermatology Reports | Issue 2/2018

Abstract

Purpose of Review

Cutaneous T cell lymphoma (CTCL) is a heterogeneous group of non-Hodgkin’s lymphoma primarily affecting the skin, of which mycosis fungoides (MF) and Sézary syndrome (SS) account for the majority of cases. The pathogenesis of CTCL is poorly understood with no strongly associated environmental or genetic risk factors identified to date. As such, the development of disease-specific therapies has been limited by a lack of understanding of potentially actionable targets. Moreover, the diagnosis of CTCL remains challenging with nonspecific diagnostic criteria, especially in early-stage disease.

Recent Findings

The advent of high-throughput sequencing techniques and molecular modalities has provided significant insight into disease pathogenesis, diagnosis, and potential therapies.

Summary

Here, we review the classic features of CTCL, focusing on MF/SS, and provide updates on our understanding of this disease.

Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973–2002. Arch Dermatol. 2007;143:854–9.CrossRefPubMed

Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood. 2009;113:5064–73.CrossRefPubMedPubMedCentral

Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768–85.CrossRefPubMed

Korgavkar K, Weinstock MA. Changing incidence trends of cutaneous B-cell lymphoma. The Journal of investigative dermatology. 2014;134:840–2.CrossRefPubMed

Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010;28:4730–9.CrossRef

Hodak E, Lapidoth M, Kohn K, David D, Brautbar B, Kfir K, et al. Mycosis fungoides: HLA class II associations among Ashkenazi and non-Ashkenazi Jewish patients. Br J Dermatol. 2001;145:974–80.CrossRefPubMed

Wohl Y, Tur E. Environmental risk factors for mycosis fungoides. Curr Probl Dermatol. 2007;35:52–64.CrossRefPubMed

Morales Suarez-Varela MM, Olsen J, Kaerlev L, Guenel P, Arveux P, Wingren G, et al. Are alcohol intake and smoking associated with mycosis fungoides? A European multicentre case-control study. Eur J Cancer. 2001;37:392–7.CrossRefPubMed

Morales-Suarez-Varela MM, Olsen J, Johansen P, Kaerlev L, Guenel P, Arveux P, et al. Occupational sun exposure and mycosis fungoides: a European multicenter case-control study. J Occup Environ Med. 2006;48:390–3.CrossRefPubMed

10.

•• da Silva Almeida AC, Abate F, Khiabanian H, Martinez-Escala E, Guitart J, Tensen CP, et al. The mutational landscape of cutaneous T cell lymphoma and Sezary syndrome. Nat Genet. 2015;47:1465–70. This is a landmark study of genetic aberrations in CTCL. CrossRefPubMedPubMedCentral

11.

Park J, Yang J, Wenzel AT, Ramachandran A, Lee WJ, Daniels JC, et al. Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E). Blood. 2017;130:1430–40.CrossRefPubMedPubMedCentral

12.

Litvinov IV, Tetzlaff MT, Thibault P, Gangar P, Moreau L, Watters AK, et al. Gene expression analysis in cutaneous T-cell lymphomas (CTCL) highlights disease heterogeneity and potential diagnostic and prognostic indicators. Oncoimmunology. 2017;6:e1306618.CrossRefPubMedPubMedCentral

13.

•• McGirt LY, Jia P, Baerenwald DA, Duszynski RJ, Dahlman KB, Zic JA, et al. Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides. Blood. 2015;126:508–19. This is another landmark study of genetic aberrations in CTCL. CrossRefPubMedPubMedCentral

14.

•• Choi J, Goh G, Walradt T, Hong BS, Bunick CG, Chen K, et al. Genomic landscape of cutaneous T cell lymphoma. Nat Genet. 2015;47:1011–9. This is a third landmark study of genetic aberrations in CTCL. CrossRefPubMedPubMedCentral

15.

Kamarashev J, Burg G, Kempf W, Hess Schmid M, Dummer R. Comparative analysis of histological and immunohistological features in mycosis fungoides and Sezary syndrome. J Cutan Pathol. 1998;25:407–12.CrossRefPubMed

16.

Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood. 2010;116:767–71.CrossRefPubMedPubMedCentral

17.

Saed G, Fivenson DP, Naidu Y, Nickoloff BJ. Mycosis fungoides exhibits a Th1-type cell-mediated cytokine profile whereas Sezary syndrome expresses a Th2-type profile. The Journal of investigative dermatology. 1994;103:29–33.CrossRefPubMed

18.

Kallinich T, Muche JM, Qin S, Sterry W, Audring H, Kroczek RA. Chemokine receptor expression on neoplastic and reactive T cells in the skin at different stages of mycosis fungoides. The Journal of investigative dermatology. 2003;121:1045–52.CrossRefPubMed

19.

Wong HK, Mishra A, Hake T, Porcu P. Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Br J Haematol. 2011;155:150–66.CrossRefPubMedPubMedCentral

20.

Barba G, Matteucci C, Girolomoni G, Brandimarte L, Varasano E, Martelli MF, et al. Comparative genomic hybridization identifies 17q11.2 approximately q12 duplication as an early event in cutaneous T-cell lymphomas. Cancer Genet Cytogenet. 2008;184:48–51.CrossRefPubMed

21.

Caprini E, Cristofoletti C, Arcelli D, Fadda P, Citterich MH, Sampogna F, et al. Identification of key regions and genes important in the pathogenesis of Sezary syndrome by combining genomic and expression microarrays. Cancer Res. 2009;69:8438–46.CrossRefPubMed

22.

Vermeer MH, van Doorn R, Dijkman R, Mao X, Whittaker S, van Voorst Vader PC, et al. Novel and highly recurrent chromosomal alterations in Sezary syndrome. Cancer Res. 2008;68:2689–98.CrossRefPubMed

23.

Salgado R, Gallardo F, Servitje O, Estrach T, Garcia-Muret MP, Romagosa V, et al. Absence of TCR loci chromosomal translocations in cutaneous T-cell lymphomas. Cancer genetics. 2011;204:405–9.CrossRefPubMed

24.

Woollard WJ, Pullabhatla V, Lorenc A, Patel VM, Butler RM, Bayega A, et al. Candidate driver genes involved in genome maintenance and DNA repair in Sezary syndrome. Blood. 2016;127:3387–97.CrossRefPubMed

25.

Ballabio E, Mitchell T, van Kester MS, Taylor S, Dunlop HM, Chi J, et al. MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential. Blood. 2010;116:1105–13.CrossRefPubMedPubMedCentral

26.

Ralfkiaer U, Hagedorn PH, Bangsgaard N, Lovendorf MB, Ahler CB, Svensson L, et al. Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood. 2011;118:5891–900.CrossRefPubMedPubMedCentral

27.

Narducci MG, Arcelli D, Picchio MC, Lazzeri C, Pagani E, Sampogna F, et al. MicroRNA profiling reveals that miR-21, miR486 and miR-214 are upregulated and involved in cell survival in Sezary syndrome. Cell Death Dis. 2011;2:e151.CrossRefPubMedPubMedCentral

28.

Marosvari D, Teglasi V, Csala I, Marschalko M, Bodor C, Timar B, et al. Altered microRNA expression in folliculotropic and transformed mycosis fungoides. Pathology oncology research : POR. 2015;21:821–5.CrossRefPubMed

29.

Ralfkiaer U, Lindahl LM, Litman T, Gjerdrum LM, Ahler CB, Gniadecki R, et al. MicroRNA expression in early mycosis fungoides is distinctly different from atopic dermatitis and advanced cutaneous T-cell lymphoma. Anticancer Res. 2014;34:7207–17.PubMed

30.

Pimpinelli N, Olsen EA, Santucci M, Vonderheid E, Haeffner AC, Stevens S, et al. Defining early mycosis fungoides. J Am Acad Dermatol. 2005;53:1053–63.CrossRefPubMed

31.

Martinez-Escala ME, Kantor RW, Cices A, Zhou XA, Kaplan JB, Pro B, et al. CD8+ mycosis fungoides: a low-grade lymphoproliferative disorder. J Am Acad Dermatol. 2017;77:489–96.CrossRefPubMed

32.

Bergman R, Faclieru D, Sahar D, Sander CA, Kerner H, Ben-Aryeh Y, et al. Immunophenotyping and T-cell receptor gamma gene rearrangement analysis as an adjunct to the histopathologic diagnosis of mycosis fungoides. J Am Acad Dermatol. 1998;39:554–9.CrossRefPubMed

33.

Ormsby A, Bergfeld WF, Tubbs RR, Hsi ED. Evaluation of a new paraffin-reactive CD7 T-cell deletion marker and a polymerase chain reaction-based T-cell receptor gene rearrangement assay: implications for diagnosis of mycosis fungoides in community clinical practice. J Am Acad Dermatol. 2001;45:405–13.CrossRefPubMed

34.

Vermeer MH, Geelen FA, Kummer JA, Meijer CJ, Willemze R. Expression of cytotoxic proteins by neoplastic T cells in mycosis fungoides increases with progression from plaque stage to tumor stage disease. Am J Pathol. 1999;154:1203–10.CrossRefPubMedPubMedCentral

35.

Ponti R, Quaglino P, Novelli M, Fierro MT, Comessatti A, Peroni A, et al. T-cell receptor gamma gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sezary syndrome) and benign inflammatory disease: correlation with clinical, histological and immunophenotypical findings. Br J Dermatol. 2005;153:565–73.CrossRefPubMed

36.

Sandberg Y, van Gastel-Mol EJ, Verhaaf B, Lam KH, van Dongen JJ, Langerak AW. BIOMED-2 multiplex immunoglobulin/T-cell receptor polymerase chain reaction protocols can reliably replace Southern blot analysis in routine clonality diagnostics. J Mol Diagn. 2005;7:495–503.CrossRefPubMedPubMedCentral

37.

Thurber SE, Zhang B, Kim YH, Schrijver I, Zehnder J, Kohler S. T-cell clonality analysis in biopsy specimens from two different skin sites shows high specificity in the diagnosis of patients with suggested mycosis fungoides. J Am Acad Dermatol. 2007;57:782–90.CrossRefPubMed

38.

Walsh NM, Prokopetz R, Tron VA, Sawyer DM, Watters AK, Murray S, et al. Histopathology in erythroderma: review of a series of cases by multiple observers. J Cutan Pathol. 1994;21:419–23.CrossRefPubMed

39.

Boonk SE, Zoutman WH, Marie-Cardine A, van der Fits L, Out-Luiting JJ, Mitchell TJ, et al. Evaluation of immunophenotypic and molecular biomarkers for Sezary syndrome using standard operating procedures: a multicenter study of 59 patients. The Journal of investigative dermatology. 2016;136:1364–72.CrossRefPubMed

40.

Vonderheid EC, Pena J, Nowell P. Sezary cell counts in erythrodermic cutaneous T-cell lymphoma: implications for prognosis and staging. Leukemia & lymphoma. 2006;47:1841–56.CrossRef

41.

Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110:1713–22.CrossRefPubMed

42.

Kim YH, Jensen RA, Watanabe GL, Varghese A, Hoppe RT. Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. Arch Dermatol. 1996;132:1309–13.CrossRefPubMed

43.

Talpur R, Singh L, Daulat S, Liu P, Seyfer S, Trynosky T, et al. Long-term outcomes of 1,263 patients with mycosis fungoides and Sezary syndrome from 1982 to 2009. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012;18:5051–60.CrossRef

44.

• Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, et al. Cutaneous Lymphoma International Consortium study of outcome in advanced stages of mycosis fungoides and sezary syndrome: effect of specific prognostic markers on survival and development of a prognostic model. J Clin Oncol. 2015;33:3766–73. This is a collaborative multicountry study put on by the Cutaneous Lymphoma International Consortium to identifiy prognostic markers in CTCL. CrossRefPubMedPubMedCentral

45.

Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003;139:857–66.PubMed

46.

Lefeber WP, Robinson JK, Clendenning WE, Dunn JL, Colton T. Attempts to enhance light microscopic diagnosis of cutaneous T-cell lymphoma (mycosis fungoides). Arch Dermatol. 1981;117:408–11.CrossRefPubMed

47.

Olerud JE, Kulin PA, Chew DE, Carlsen RA, Hammar SP, Weir TW, et al. Cutaneous T-cell lymphoma. Evaluation of pretreatment skin biopsy specimens by a panel of pathologists. Arch Dermatol. 1992;128:501–7.CrossRefPubMed

48.

Santucci M, Biggeri A, Feller AC, Burg G. Accuracy, concordance, and reproducibility of histologic diagnosis in cutaneous T-cell lymphoma: an EORTC Cutaneous Lymphoma Project Group Study. European Organization for Research and Treatment of Cancer. Arch Dermatol. 2000;136:497–502.CrossRefPubMed

49.

Tok J, Szabolcs MJ, Silvers DN, Zhong J, Matsushima AY. Detection of clonal T-cell receptor gamma chain gene rearrangements by polymerase chain reaction and denaturing gradient gel electrophoresis (PCR/DGGE) in archival specimens from patients with early cutaneous T-cell lymphoma: correlation of histologic findings with PCR/DGGE. J Am Acad Dermatol. 1998;38:453–60.CrossRefPubMed

50.

Zhang B, Beck AH, Taube JM, Kohler S, Seo K, Zwerner J, et al. Combined use of PCR-based TCRG and TCRB clonality tests on paraffin-embedded skin tissue in the differential diagnosis of mycosis fungoides and inflammatory dermatoses. J Mol Diagn. 2010;12:320–7.CrossRefPubMedPubMedCentral

51.

Robins HS, Campregher PV, Srivastava SK, Wacher A, Turtle CJ, Kahsai O, et al. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood. 2009;114:4099–107.CrossRefPubMedPubMedCentral

52.

•• Kirsch IR, Watanabe R, O'Malley JT, Williamson DW, Scott LL, Elco CP, et al. TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL. Sci Trans Med. 2015;7:308ra158. This is a landmark study of TCR sequencing for identification of malignant T cells in CTCL. CrossRef

53.

Sufficool KE, Lockwood CM, Abel HJ, Hagemann IS, Schumacher JA, Kelley TW, et al. T-cell clonality assessment by next-generation sequencing improves detection sensitivity in mycosis fungoides. J Am Acad Dermatol. 2015;73:228–236 e222.CrossRefPubMed

54.

Weng WK, Armstrong R, Arai S, Desmarais C, Hoppe R, Kim YH. Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma. Sci Transl Med. 2013;5:214ra171.CrossRefPubMed

55.

Feng B, Jorgensen JL, Jones D, Chen SS, Hu Y, Medeiros LJ, et al. Flow cytometric detection of peripheral blood involvement by mycosis fungoides and Sezary syndrome using T-cell receptor Vbeta chain antibodies and its application in blood staging. Mod Pathol. 2010;23:284–95.CrossRefPubMed

56.

Clark RA, Shackelton JB, Watanabe R, Calarese A, Yamanaka K, Campbell JJ, et al. High-scatter T cells: a reliable biomarker for malignant T cells in cutaneous T-cell lymphoma. Blood. 2011;117:1966–76.CrossRefPubMedPubMedCentral

57.

Dulmage B O, Akilov O, Vu J R, Falo L D, Geskin L J. Dysregulation of the TOX-RUNX3 pathway in cutaneous T-cell lymphoma. Oncotarget 2015.

58.

Zhang Y, Wang Y, Yu R, Huang Y, Su M, Xiao C, et al. Molecular markers of early-stage mycosis fungoides. J Investigative Dermatol. 2012;132:1698–706.CrossRef

59.

Litvinov IV, Netchiporouk E, Cordeiro B, Dore MA, Moreau L, Pehr K, et al. The use of transcriptional profiling to improve personalized diagnosis and management of cutaneous T-cell lymphoma (CTCL). Clin Cancer Res. 2015;21:2820–9.CrossRefPubMedPubMedCentral

60.

• Rook AH, Gelfand JM, Wysocka M, Troxel AB, Benoit B, Surber C, et al. Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma. Blood. 2015;126:1452–61. Important initial study of the topical immunomodulator resiquimod in the treatment of early-stage CTCL. CrossRefPubMedPubMedCentral

61.

Lundin J, Hagberg H, Repp R, Cavallin-Stahl E, Freden S, Juliusson G, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood. 2003;101:4267–72.CrossRefPubMed

62.

Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014;32:1157–63.CrossRefPubMed

63.

•• Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet (London, England). 2017;390:555–66. This is a phase 3 clinical trial that demonstrated the effectiveness of brentuximab vedotin, an anti-CD30 monoclonal antibody conjugated to a tubulin inhibitor, compared with physician’s choice for treatment of CTCL. CrossRef

64.

Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34:2698–704.CrossRefPubMedPubMedCentral

65.

Khodadoust M, Rook AH, Porcu P, Foss FM, Moskowitz AJ, Shustov AR, et al. Pembrolizumab for treatment of relapsed/refractory mycosis fungoides and Sezary syndrome: clinical efficacy in a CITN multicenter phase 2 study. Blood. 2016;128:181.

66.

Marie-Cardine A, Viaud N, Thonnart N, Joly R, Chanteux S, Gauthier L, et al. IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma. Cancer Res. 2014;74:6060–70.CrossRefPubMed

67.

Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Dyer MJ, et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res. 1998;22:185–91.CrossRefPubMed

68.

Thursky KA, Worth LJ, Seymour JF, Miles Prince H, Slavin MA. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br J Haematol. 2006;132:3–12.CrossRefPubMed

69.

Bernengo MG, Quaglino P, Comessatti A, Ortoncelli M, Novelli M, Lisa F, et al. Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients. Haematologica. 2007;92:784–94.CrossRefPubMed

70.

Sugaya M, Morimura S, Suga H, Kawaguchi M, Miyagaki T, Ohmatsu H, et al. CCR4 is expressed on infiltrating cells in lesional skin of early mycosis fungoides and atopic dermatitis. J Dermatol. 2015;42:613–5.CrossRefPubMed

71.

Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30:837–42.CrossRefPubMed

72.

Duvic M, Pinter-Brown LC, Foss FM, Sokol L, Jorgensen JL, Challagundla P, et al. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 2015;125:1883–9.CrossRefPubMedPubMedCentral

73.

• Ni X, Jorgensen JL, Goswami M, Challagundla P, Decker WK, Kim YH, et al. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sezary syndrome. Clin Cancer Res. 2015;21:274–85. This study highlights the treatment potential of mogalmulizumab, an anti-CCR4 antibody, in treatment of CTCL. CrossRefPubMed

74.

Sugio T, Kato K, Aoki T, Ohta T, Saito N, Yoshida S, et al. Mogamulizumab treatment prior to allogeneic hematopoietic stem cell transplantation induces severe acute graft-versus-host disease. Biol Blood Marrow Trans. 2016;22:1608–14.CrossRef

75.

Kim YH, Tavallaee M, Sundram U, Salva KA, Wood GS, Li S, et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sezary syndrome with variable CD30 expression level: a multi-institution collaborative project. J Clin Oncol. 2015;33:3750–8.CrossRefPubMedPubMedCentral

76.

Duvic M, Tetzlaff MT, Gangar P, Clos AL, Sui D, Talpur R. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol. 2015;33:3759–65.CrossRefPubMedPubMedCentral

77.

Sicard H, Bonnafous C, Morel A, Bagot M, Bensussan A, Marie-Cardine A. A novel targeted immunotherapy for CTCL is on its way: anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies. Oncoimmunology. 2015;4:e1022306.CrossRefPubMedPubMedCentral

78.

Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013;19:3462–73.CrossRefPubMedPubMedCentral

79.

Kantekure K, Yang Y, Raghunath P, Schaffer A, Woetmann A, Zhang Q, et al. Expression patterns of the immunosuppressive proteins PD-1/CD279 and PD-L1/CD274 at different stages of cutaneous T-cell lymphoma/mycosis fungoides. Am J Dermatopathol. 2012;34:126–8.CrossRefPubMedPubMedCentral

80.

Virmani P, Zain J, Rosen ST, Myskowski PL, Querfeld C. Hematopoietic stem cell transplant for mycosis fungoides and Sezary syndrome. Dermatol Clin. 2015;33:807–18.CrossRefPubMed

81.

Duarte RF, Canals C, Onida F, Gabriel IH, Arranz R, Arcese W, et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010;28:4492–9.CrossRefPubMed

82.

Benjamin J, Chhabra S, Kohrt HE, Lavori P, Laport GG, Arai S, et al. Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms. Biol Blood Marrow Trans. 2014;20:837–43.CrossRef

83.

Bearman SI. Reduced-intensity allogeneic stem cell transplantation. Curr Hematol Rep. 2003;2:277–86.PubMed

84.

Baron F, Labopin M, Peniket A, Jindra P, Afanasyev B, Sanz MA, et al. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Cancer. 2015;121:1048–55.CrossRefPubMed

85.

Dulmage B, Geskin L, Guitart J, Akilov O E. The biomarker landscape in mycosis fungoides and Sezary syndrome. 2017; 26:668–676.

Title: What Is New in CTCL—Pathogenesis, Diagnosis, and Treatments
Authors: Brittany O. Dulmage
Betty Y. Kong
Kassandra Holzem
Joan Guitart
Publication date: 01-06-2018
Publisher: Springer US
Published in: Current Dermatology Reports / Issue 2/2018
Electronic ISSN: 2162-4933
DOI: https://doi.org/10.1007/s13671-018-0214-0

2024 ASCO Annual Meeting

Springer Medicine

What Is New in CTCL—Pathogenesis, Diagnosis, and Treatments

Abstract

Purpose of Review

Recent Findings

Summary

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 2/2018

Use of Dermoscopy to Diagnose and Select BCCs that can be Treated Empirically

Actinic Keratosis—Can Dermoscopy or RCM Differentiate AK (Not Full Thickness Atypia) from Full-Thickness Atypia/Invasive SCC?

IL-23 Inhibitors for Psoriasis

Confocal Microscopy in Skin Cancer

Risk Stratification: Should All Actinic Keratoses in All Patients Be Treated?